Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic546 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Regulatory
52 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
Data updated 9 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Dasatinib | 16 | 6 | 10 |
| Prednisone | 11 | 11 | 0 |
| Mercaptopurine | 8 | 0 | 7 |
| Thioguanine | 8 | 0 | 7 |
| Arabinosylguanine | 4 | 1 | 3 |
| Imatinib | 4 | 3 | 1 |
| Nelarabine | 4 | 1 | 3 |
| Cytarabine | 3 | 0 | 3 |
| Doxorubicin | 3 | 0 | 3 |
| Gemcitabine | 3 | 0 | 3 |
| Ibrutinib | 3 | 3 | 0 |
| Ponatinib | 3 | 2 | 1 |
| Prednisolone | 3 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 0 |
| 3 |
| Bosutinib | 2 | 1 | 1 |
| Nilotinib | 2 | 1 | 1 |
| Ruxolitinib | 2 | 2 | 0 |
| Sunitinib | 2 | 2 | 0 |
| Adavosertib | 1 | 1 | 0 |
| Axitinib | 1 | 0 | 1 |
| Azathioprine | 1 | 0 | 0 |
| Chemotherapy | 1 | 1 | 0 |
| Crenolanib | 1 | 1 | 0 |
| Erlotinib | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| GSK126 | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| Selumetinib | 1 | 1 | 0 |
| Sirolimus | 1 | 1 | 0 |
| Sorafenib | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tofacitinib | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.